Positive results from the HIMALAYA phase III trial showed a single priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in overall survival versus Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.
Performance data for a second-generation Cologuard (multi-target stool DNA) test showed an overall sensitivity of 95.2% for colorectal cancer at specificity of 92.4% for negative samples confirmed by colonoscopy.
A team of researchers with the UC Davis Comprehensive Cancer Center found that even with expanded access to Medi-Cal health coverage, Latino smokers in California continue to get less help than non-Latino white people quitting smoking.
Researchers at Fox Chase Cancer Center found that disparities in the incidence of head and neck cancer are driven by behavioral and environmental risk factors rather than race.
A data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians aims to help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.
MD Anderson Cancer Center and Yingli Pharma US Inc. entered a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.
TriSalus Life Sciences and the University of Colorado Anschutz Medical Campus entered a strategic research collaboration to advance research of immuno-oncology treatments for patients with liver and pancreatic tumors.
A collaborative research team led by scientists from Roswell Park Comprehensive Cancer Center and Wake Forest University Baptist Medical Center has determined that a GTPase called RAC1 actively recruits enzymes involved in nucleotide production to promote cancer metastasis.
Researchers from Jonsson Comprehensive Cancer Center at UCLA have illuminated molecular “crosstalk” in pancreatic cancer cells, identifying vulnerabilities that could provide a target for therapeutic drugs already being studied in several cancers.
For patients with acute lymphoblastic leukemia carrying the Philadelphia chromosome and whose disease relapsed after allogeneic hematopoietic stem cell transplantation, the two-year overall survival rate nearly doubled from 2000-2004 to 2015-2019, according to a study published in Clinical Cancer Research.
